| Jun 12 |
Insider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ...
|
| Jun 10 |
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Jun 4 |
17 Analysts Have This To Say About Crinetics Pharmaceuticals
|
| Jun 3 |
Crinetics Unveils 'Stunning' Results In Highly Anticipated Study
|
| Jun 3 |
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
|
| Jun 3 |
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
|
| Jun 1 |
Shareholders Will Probably Not Have Any Issues With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation
|
| May 31 |
Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...
|
| May 30 |
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
|
| May 23 |
Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data
|
